-- In collaboration with Dr. Steven Abramson, Director of the Division of
Rheumatology at the Hospital for Joint Diseases of New York University
Medical Center, Interleukin has initiated a study on the genetics of
-- An Interleukin Genetics study published in Nutrition reported that a
botanical supplement that included rose hips, a blueberry and
blackberry mixture and a grape vine extract, reduced inflammation more
effectively in individuals with genetic variations that are associated
with over-expression of inflammation and risk for early heart attacks.
-- The Company continues to expand its scientific advisory board, having
recently announced the addition of Dr. Emad E-Omar, a gastric cancer
expert and Drs. James Meigs and John Foreyt, both obesity/diabetes
management experts. These three advisors will help to guide
Interleukin's development programs in key growth areas related to
obesity and weight management, and gastric cancer.
"We are particularly excited about opportunities for Interleukin regarding gastric cancer, which is the second most common cause of cancer deaths worldwide", added Ken Kornman, President and Chief Scientific Officer. "Utilizing our research and proprietary genetic technology in the field of inflammation, we expect to develop tests that will contribute towards improving the prevention and medical management of gastric cancer. We plan to conduct studies in Asia in 2008 and anticipate having a product in the marketplace in the second half of 2009. We are also making good advances on the development of our weight loss test and expect to begin studies in medical weight loss clinics in the U.S. in 2008."
Research and development expenses were $786,000 compared to $721,000
for the third quarter of 2006. This increase primarily reflects the timing
of third party costs related to
|SOURCE Interleukin Genetics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved